AQST Q2 2024 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$20M+51.8% YoY

Gross Profit

$16M77.5% margin

Operating Income

$55,0000.3% margin

Net Income

-$3M-13.7% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+66.8%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$118M

Total Liabilities

$153M

Stockholders' Equity

-$35M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$13M	+51.8%
Gross Profit	$16M	$7M	+135.1%
Operating Income	$55,000	-$4M	+101.3%
Net Income	-$3M	-$6M	+52.6%

Revenue Segments

License and Royalty Revenue

$11M56%

Manufacture and Supply Revenue

$8M40%

Co-Development and Research Fees

$756,0004%

Geographic Segments

Non-US

$10M52%

UNITED STATES

$10M48%